These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 12673886)

  • 1. Expression of folylpolyglutamyl synthetase predicts poor response to methotrexate therapy in patients with rheumatoid arthritis.
    Stranzl T; Wolf J; Leeb BF; Smolen JS; Pirker R; Filipits M
    Clin Exp Rheumatol; 2003; 21(1):27-32. PubMed ID: 12673886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of altered folylpolyglutamate synthetase pre-mRNA splicing with methotrexate unresponsiveness in early rheumatoid arthritis.
    Muller IB; Lin M; Lems WF; Ter Wee MM; Wojtuszkiewicz A; Nurmohamed MT; Cloos J; Assaraf YG; Jansen G; de Jonge R
    Rheumatology (Oxford); 2021 Mar; 60(3):1273-1281. PubMed ID: 32940699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploratory analysis of four polymorphisms in human GGH and FPGS genes and their effect in methotrexate-treated rheumatoid arthritis patients.
    van der Straaten RJ; Wessels JA; de Vries-Bouwstra JK; Goekoop-Ruiterman YP; Allaart CF; Bogaartz J; Tiller M; Huizinga TW; Guchelaar HJ
    Pharmacogenomics; 2007 Feb; 8(2):141-50. PubMed ID: 17286537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methotrexate pharmacokinetic genetic variants are associated with outcome in rheumatoid arthritis patients.
    Moya P; Salazar J; Arranz MJ; Díaz-Torné C; del Río E; Casademont J; Corominas H; Baiget M
    Pharmacogenomics; 2016; 17(1):25-9. PubMed ID: 26652611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The influence of methotrexate on the gene expression of the pro-inflammatory cytokine IL-12A in the therapy of rheumatoid arthritis.
    Hobl EL; Mader RM; Erlacher L; Duhm B; Mustak M; Bröll H; Högger P; Kalipciyan M; Jilma B
    Clin Exp Rheumatol; 2011; 29(6):963-9. PubMed ID: 22133036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study.
    Smolen JS; Han C; Bala M; Maini RN; Kalden JR; van der Heijde D; Breedveld FC; Furst DE; Lipsky PE;
    Arthritis Rheum; 2005 Apr; 52(4):1020-30. PubMed ID: 15818697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contemporary use of disease-modifying drugs in the management of patients with early rheumatoid arthritis in Norway.
    Nikolaisen C; Kvien TK; Mikkelsen K; Kaufmann C; Rødevand E; Nossent JC
    Scand J Rheumatol; 2009; 38(4):240-5. PubMed ID: 19229766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myeloid-related Protein 8/14 Levels in Rheumatoid Arthritis: Marker of Disease Activity and Response to Methotrexate.
    Patro PS; Singh A; Misra R; Aggarwal A
    J Rheumatol; 2016 Apr; 43(4):731-7. PubMed ID: 26834220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levofloxacin treatment in patients with rheumatoid arthritis receiving methotrexate.
    Ogrendik M
    South Med J; 2007 Feb; 100(2):135-9. PubMed ID: 17330681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of resistance markers to methotrexate predicts clinical improvement in patients with rheumatoid arthritis.
    Wolf J; Stranzl T; Filipits M; Pohl G; Pirker R; Leeb B; Smolen JS
    Ann Rheum Dis; 2005 Apr; 64(4):564-8. PubMed ID: 15345497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Soluble cell adhesion molecules (sICAM-1, sVCAM-1, and sE-selectin) in patients with early rheumatoid arthritis.
    Klimiuk PA; Fiedorczyk M; Sierakowski S; Chwiecko J
    Scand J Rheumatol; 2007; 36(5):345-50. PubMed ID: 17963163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors associated with radiographic progression in patients with rheumatoid arthritis who were treated with methotrexate.
    Weinblatt ME; Keystone EC; Cohen MD; Freundlich B; Li J; Chon Y; Baumgartner SW
    J Rheumatol; 2011 Feb; 38(2):242-6. PubMed ID: 21078715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiologic damage at baseline predicts patient-related outcomes 18 years after the initiation of methotrexate therapy in patients with severe rheumatoid arthritis.
    Krause D; Gabriel B; Herborn G; Braun J; Rau R
    Clin Exp Rheumatol; 2015; 33(5):611-6. PubMed ID: 26315962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longterm combination therapy of refractory and destructive rheumatoid arthritis with methotrexate (MTX) and intramuscular gold or other disease modifying antirheumatic drugs compared to MTX monotherapy.
    Rau R; Schleusser B; Herborn G; Karger T
    J Rheumatol; 1998 Aug; 25(8):1485-92. PubMed ID: 9712088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: a six-month, double-blind, randomized, dose-ranging study.
    Furst DE; Saag K; Fleischmann MR; Sherrer Y; Block JA; Schnitzer T; Rutstein J; Baldassare A; Kaine J; Calabrese L; Dietz F; Sack M; Senter RG; Wiesenhutter C; Schiff M; Stein CM; Satoi Y; Matsumoto A; Caldwell J; Harris RE; Moreland LW; Hurd E; Yocum D; Stamler DA
    Arthritis Rheum; 2002 Aug; 46(8):2020-8. PubMed ID: 12209503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, double-blind, parallel, single-site pilot trial to compare two different starting doses of methotrexate in methotrexate-naïve adult patients with rheumatoid arthritis.
    Hobl EL; Mader RM; Jilma B; Duhm B; Mustak M; Bröll H; Högger P; Erlacher L
    Clin Ther; 2012 May; 34(5):1195-203. PubMed ID: 22516039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genome-wide analysis of methotrexate pharmacogenomics in rheumatoid arthritis shows multiple novel risk variants and leads for TYMS regulation.
    Senapati S; Singh S; Das M; Kumar A; Gupta R; Kumar U; Jain S; Juyal RC; Thelma BK
    Pharmacogenet Genomics; 2014 Apr; 24(4):211-9. PubMed ID: 24583629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of the clinical use of iguratimod therapy in patients with rheumatoid arthritis.
    Okamura K; Yonemoto Y; Okura C; Kobayashi T; Takagishi K
    Mod Rheumatol; 2015 Mar; 25(2):235-40. PubMed ID: 25065917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Choice of second-line disease-modifying antirheumatic drugs after failure of methotrexate therapy for rheumatoid arthritis: a decision tree for clinical practice based on rheumatologists' preferences.
    Fautrel B; Guillemin F; Meyer O; de Bandt M; Berthelot JM; Flipo RM; Lioté F; Maillefert JF; Wendling D; Saraux A; Combe B; Le Loët X; ; ;
    Arthritis Rheum; 2009 Apr; 61(4):425-34. PubMed ID: 19333993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Folyl polyglutamate synthethase (FPGS) gene polymorphisms may influence methotrexate adverse events in South Indian Tamil Rheumatoid Arthritis patients.
    Muralidharan N; Sundaram R; Kodidela S; Chengappa KG; Mariaselvam CM; Misra DP; Negi VS
    Pharmacogenomics J; 2020 Apr; 20(2):342-349. PubMed ID: 31611592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.